Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.

Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients.  The list price for Eliquis (apixaban) is ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

These five blue-chip dividend stocks have had a tough 2025 but are solid long-term buys for growth and income investors.

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Pharmaceutical companies have been in talks with the U.S. government to figure out how to bring drug prices down after President Trump signed in May an executive order that ties U.S. prices to the ...